InnovAge (NASDAQ: INNV) revenue
InnovAge reported revenue of $989.7m for fiscal 2026, 15.9% more than in fiscal 2025 ($853.7m). Since fiscal 2020 its revenue has grown by 74.5%, an average growth of 9.7% a year.
InnovAge has grown its revenue for 3 years in a row, and fiscal 2026 is the highest of its 7 fiscal years on record. The biggest drop was in fiscal 2023, −1.5%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2026 | $989.7m | +15.9% | $2.6m | 0.3% |
| 2025 | $853.7m | +11.8% | −$29.8m | −3.5% |
| 2024 | $763.9m | +11.0% | −$23.2m | −3.0% |
| 2023 | $688.1m | −1.5% | −$49.4m | −7.2% |
| 2022 | $698.6m | +9.5% | −$4.4m | −0.6% |
| 2021 | $637.8m | +12.4% | −$12.3m | −1.9% |
| 2020 | $567.2m | — | $50.9m | 9.0% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
InnovAge revenue compared with its sector
By revenue for its latest fiscal year, InnovAge ranks 149th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; InnovAge, 15.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 147th | Acadia Pharmaceuticals | $1,072m | 11.9% |
| 148th | Tandem Diabetes Care | $1,015m | 7.9% |
| 149th | InnovAge | $989.7m | 15.9% |
| 150th | Guardant Health | $982.0m | 32.9% |
| 151st | Claritev | $965.4m | 3.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of InnovAge
- How much revenue did InnovAge make in fiscal 2026?
- InnovAge reported revenue of $989.7m for fiscal 2026, compared with $853.7m in fiscal 2025.
- How much has the revenue of InnovAge grown?
- Between fiscal 2020 and fiscal 2026 it went from $567.2m to $989.7m: 74.5% more, an average growth of 9.7% a year.
- What was the best year for revenue at InnovAge?
- Of its last 7 fiscal years, fiscal 2026, with $989.7m.
- Where does InnovAge rank in its sector by revenue?
- It ranks 149th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for InnovAge come from?
- From the annual report (Form 10-K) that InnovAge files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that InnovAge files with the SEC. The filing for each fiscal year: 2026 · 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on InnovAge: the InnovAge page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.